Sugammadex Reduces Antiemetic Effect of Dexamethasone

Status

Not yet recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06901596

Enrollment

100

Registered

2025-03-30

Start date

2025-04-01

Completion date

2025-07-15

Last updated

2025-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

PONV

Keywords

sugammadex, dexamethasone, PONV, perioperative, surgery

Brief summary

Sugammadex is a medication used for reversal of muscle relaxation during procedures under general anesthesia. It works by encapsulating muscle relaxant molecules with a steroid ring in its structure. On the other hand, postoporative nause and vomiting (PONV) is an adverse outcome during anesthesia. PONV can be prevented with pharmacologic agents such as ondansetron and dexamethasone. Dexamethasone is a steroidal agent that can interact with sugammadex. In theory, this interaction could lead to reduced effectiveness of sugammadex. In fact, several studies have explored this interaction. However, the effect of sugammadex on the antiemetic effect of dexamethasone has not been evaluated. This study intends to evaluate this interaction.

Detailed description

The study will use de-identified retrospective data to conduct a cross-sectional study to determine the effect of sugammadex on the antiemetic efficacy of dexamethasone in elective adult surgical patients who underwent surgery in a tertiary care center between January 1 2023 and January 1 2024 . The investigators will conduct univariate and multivariate analysis to assess the effect.

Interventions

None listed

Study design

Observational model

CASE_CONTROL

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Older than 18 years old * Elective surgery * ASA 1, 2, 3 * At least one risk factor for PONV

Exclusion criteria

* Pregnancy * Receiving antiemetics prior to arrival to preoperative holding area * Receiving opioids prior to arrival to preoperative holding area * Admission to ICU * Altered mental status * Rapid sequence induction * Nausea or vomiting before surgery

Design outcomes

Primary

Measure	Time frame	Description
Rate of PONV	2 hours after admission to PACU	Number of events of PONV during 2 hours after admission to PACU

Contacts

Primary ContactEfrain Riveros Perez, MD

eriverosperez@augusta.edu7067217361

Outcome results